课题基金 / 基金详情

Primary prostate cancer cells as novel models for patient therapy prediction

Primary prostate cancer cells as novel models for patient therapy prediction
原发性前列腺癌细胞作为患者治疗预测的新模型
批准号：
477987
负责人：
Liu Stanley K
金额：
$64.37万
依托单位：
Sunnybrook Research Institute (Toronto, Ontario)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2023
资助国家：
加拿大
项目状态：
未结题
起止时间：
2023-03-01 至 2028-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=477987&lang=en
关键词：
Patient-Derived Cancer Cells Personalized Medicine Prostate Cancer Proteomics Therapy Prediction

项目摘要

项目成果

Liu Stanley K的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Although many people view prostate cancer as a slow growing, highly curable cancer, the reality is that up to 15% of men will present with spread (metastases) of their prostate cancer at time of diagnosis. This is an incurable situation, with up to half o
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Non-invasive multi-omics urinary biomarkers to guide prostate cancer management
海外基金